As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Each year, 500 to 1,000 people in the U.S. are diagnosed with pulmonary arterial hypertension (PAH), a progressive and often under-detected disease. To address the significant impact of this disease ...

Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...

Liquidia Technologies ( (LQDA) ) has released its Q3 earnings. Here is a breakdown of the information Liquidia Technologies presented to its ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

and it’s different from the commonly known hypertension that is just basically high blood pressure. This one is high blood ...

"The financing we concluded in October was a transformational moment for Inhibikase, and positioned us to advance IkT-001Pro ...

Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...

The management of pulmonary hypertension has already incorporated ... act principally through vasodilatation of the pulmonary arterial circulation through well-delineated mechanisms, although ...